Annual meeting moves to the New York Marriott Marquis on October 13-16, marking a new chapter and providing a refreshed ...

Images circulating online that show New York City Mayor Zohran Mamdani as a child with millionaire financier and sex offender Jeffrey Epstein are generated by artificial intelligence.

In a new study published in Cancer, researchers from the University of Alabama at Birmingham Marnix E. Heersink School of Medicine’s Department of Pathology examine this disparity more closely, ...

After a short delay and concerns of potential intervention from senior officials, the FDA has issued a draft guidance for the industry on the potential use of minimal residual disease (MRD) and ...

The FDA issued draft guidance Jan. 21 proposing the use of minimal residual disease and complete response as primary endpoints to support accelerated approval of drugs for multiple myeloma. The draft ...

Carol Meyers, 72, knew exactly how her daughter was feeling. Her daughter, Carley Yelyashov, 44, was in the hospital in June 2024 for a stem cell transplant, when healthy stem cells are infused into ...

Luciano Costa waited three years to see how patients with an aggressive bone-marrow cancer would fare on an experimental immunotherapy treatment. Reviewing the results gave him goose bumps. “Holy shit ...

Men newly diagnosed with multiple myeloma are twice as likely to present with advanced stage III disease compared to women, according to research revealing sex differences at diagnosis. Scientists at ...

Male patients with newly diagnosed multiple myeloma present with more advanced disease, showing twofold higher odds for International Staging System stage III disease and greater end-organ damage than ...

A new study maps the immune cell landscape of bone marrow in patients with multiple myeloma, a rare cancer that develops in the plasma cells of the bone marrow and has no cure. This large immune cell ...

In a phase 1–2 trial, teclistamab, a bispecific antibody targeting CD3 on T-cell surfaces and B-cell maturation antigen on myeloma cells, showed durable responses in heavily pretreated patients with ...